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The possibility that endogenous retroviruses (ERVs)
may be involved in multiple sclerosis (MS) and other
human autoimmune diseases has been investigated
intensively by several groups over the past decade,
but as yet no clear consensus view has emerged and
the topic remains controversial. The investigations in
man were stimulated initially by reports of ERV
expression in a number of mouse strains that are
genetically predisposed to autoimmune disease.1
Endogenous retroviral elements in the human
genome are stretches of DNA that are related to, and
possess significant sequence homology with,
infectious exogenous retroviruses such as human T-
cell leukaemia virus (HTLV). There are a large number
of different endogenous retroviral elements, often
present in multiple copies, and altogether they are
estimated to constitute as much as 8% of the human
genome.2 The vast majority of these elements are
defective, however, due to the presence of
accumulated mutations including deletions and stop
codons, and are therefore unable to encode viable
infectious retroviral particles. Nevertheless, a small
subset does possess intact open reading frames;
therefore, these elements have the potential to
encode, and even express, certain functional
retroviral-like proteins. The origin of endogenous
retroviral sequences is uncertain, but it is generally
thought that they represent the remnants of ancestral
retroviral infections that have become fixed within
germline DNA and are therefore inherited in a
Mendelian fashion.
Several human endogenous retroviruses (HERVs)
have been claimed as potential aetiological agents
for a variety of malignancies, autoimmune diseases
and neurological disorders.3 In some cases, such as
the proposed involvement of a human endogenous
retroviral superantigen in type 1 diabetes,4 the
findings have not proved reproducible. In many other
cases the evidence remains incomplete or has yet to
be independently confirmed. Regarding the possible
role of ERVs in MS, there has been considerable
work on ERV3 and HRES-1, discussed in detail in the
accompanying review by Jørgen Clausen (see pages
22–28 of this issue). In addition, Perron and
colleagues have published on the association
between MS and HERV-W.5
An extremely unusual HERV, HERV-W encodes a
protein with a known function. The envelope protein
of this ERV is thought to mediate fusion of
cytotrophoblasts and is therefore likely to play an
essential role in the formation of the human
placenta.2 HERV-W was originally discovered during
studies of retroviral particles associated with MS, and
was initially designated MS-associated retrovirus,
MSRV.6 The detection of virion-associated MSRV RNA
in the serum of patients with MS7 has been
independently confirmed in Sardinia, an island with
an unusually high incidence of the disease.8 Further
investigations in Sardinian patients have revealed
that MSRV expression may also be associated with
other inflammatory neurological diseases9 and that,
in MS, the detection of MSRV RNA in cerebrospinal
fluid may be a prognostic factor correlated with
disability progression.10 HERV-W has also recently
been implicated in the development of schizophrenia
but this finding has yet to be reproduced by other
groups.11
If future studies confirm the association between
MS and HERV-W, ERV-3, HRES-1 or any other
HERV,12 the question of potential pathogenic
mechanisms will become central. In the case of
HERV-W, it has been demonstrated that the envelope
protein acts as a superantigen* (referred to as an
autoantigen in Clausen’s paper**). Researchers have
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proposed that this could trigger or contribute to the
autoimmune dysregulation seen in MS.13 Evidence
suggesting that HERV-W might be associated with a
novel gliotoxin has also been presented;14 however,
it is important to recognize that for HERVs generally,
these potential pathogenic mechanisms are currently
in the realm of speculation. It remains possible that
HERV expression simply represents an
epiphenomenon and that the associations may prove
to be casual rather than causal. Although research in
this area has revealed many intriguing findings,
much more work is needed before any truly coherent
picture can be expected to emerge.
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